A D-psicose 3-epimerase mutant and its application

By constructing the optimized D-psicose-3-episomerase gene in Bacillus subtilis, the problems of low enzyme activity and limited expression are solved, and efficient D-psicose production is achieved, ensuring that security and economical.

CN116064496BActive Publication Date: 2024-12-03CHINA NAT RES INST OF FOOD & FERMENTATION IND CO LTD +3
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202211202796.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-29
Publication Date
2024-12-03
Estimated Expiration
2042-09-29

AI Technical Summary

Technical Problem

In the prior art, D-psicose-3-episomerase has host codon preference and expression amount limitations during the expression and synthesis of Bacillus subtilis, resulting in low enzyme activity and E. coli as expression The host has risks of security and environmental mutation.

Method used

By constructing recombinant genetically engineered bacteria, the amino acid sequence of D-psicose-3-episomerase was optimized by site-directed mutation method, specific promoter-ribosome binding sites were designed, and cloned and expressed in Bacillus subtilis , achieve a significant improvement in enzyme activity.

Benefits of technology

It significantly improves the enzyme activity of D-psicose-3-episomerase, simplifies the production process, reduces production costs, and ensures safe and efficient food-grade enzyme preparation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses a D-psicose 3-epimerase mutant and its application. The amino acid sequence of the D-psicose 3-epimerase is shown in the sequence table SEQ ID NO: 1, and the amino acid sequence of the mutant is shown in the sequence table SEQ ID NO: 4. The present invention overcomes the limitations of host codon preference and expression amount in the expression and synthesis process of the existing D-psicose 3-epimerase in Bacillus subtilis, and obtains a D-psicose 3-epimerase mutant by a site-directed mutagenesis method. Compared with the unmutated enzyme, the enzyme activity is greatly enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biological gene technology, and particularly relates to a D-psicose 3-epimerase mutant and application thereof. Background Art

[0002] D-psicose is a hexone monosaccharide with special health functions discovered in recent years. It is a diastereomer of D-fructose and a rare sugar with very low content in nature. Its sweetness is equivalent to 70% of sucrose, but its calories are only equivalent to 0.3% of sucrose. It is a new low-calorie sweetener and has been certified by the US FDA for use as an additive in food and diet. Allulose also has many special physiological activities and multiple health effects. It has preventive and auxiliary therapeutic effects on hyperglycemia, obesity and inflammation caused by obesity; it can regulate cholesterol metabolism and regulate intestinal microbiota to exert its biological effects; it is antioxidant, protects nerves and inhibits cancer cells. D-psicose exists naturally but its content is extremely low. It is difficult to prepare it directly, and exogenous transformation is the only way. The chemical synthesis method has a very low efficiency due to its harsh reaction conditions and many by-products. The biotransformation method has become a common preparation method due to its mild reaction conditions, little impact on the environment, and high selectivity. D-psicose 3-epimerase (DP3E) is a member of the DTEase family. It uses D-fructose as a substrate to catalyze the production of D-psicose without generating other byproducts, which facilitates subsequent separation and purification. The DP3E studied by the Wuxi team in Jiangsu Province is derived from Clostridium sp.; the DP3E studied by a team in Shanghai is derived from Burkholderia sp., and both can produce D-psicose using D-fructose as a substrate.

[0003] As DP3E from different sources was discovered, DP3E expression strains constructed by genetic engineering technology gradually appeared in patents and reports. The selected hosts are generally divided into two categories: Escherichia coli expression system and Bacillus subtilis expression system. So far, the expression host bacteria used in most literature patents are Escherichia coli. The advantages of the Escherichia coli expression system are simplicity, maturity of technology, and high expression; but the outer membrane of Escherichia coli has a lipopolysaccharide structure, which is an endotoxin that can cause disease reactions in humans and animals. In addition, Escherichia coli has the possibility of forming pathogenic bacteria due to environmental mutations, so the application of Escherichia coli in the production of food enzyme preparations has certain uncertainties, and the activity of the expressed protein is also relatively poor; Bacillus subtilis is a traditional food-grade bacterium, and a large number of enzymes expressed have been used in food raw material production for a long time, proving its safety and having the technical advantages of safety and efficiency, but its expression level is relatively low. It is urgent to study the technology that can express active DP3E in large quantities in Bacillus subtilis. Summary of the invention

[0004] The object of the present invention is to provide a D-psicose 3-epimerase mutant and application thereof.

[0005] A D-psicose 3-epimerase, the amino acid sequence of which is shown in SEQ ID NO: 1 in the sequence listing.

[0006] A D-psicose 3-epimerase gene, the nucleotide sequence of which is shown in SEQ ID NO: 2 in the sequence listing.

[0007] An expression-optimized promoter and ribosome binding site, characterized in that its nucleotide sequence is shown in SEQ ID NO: 3 in the sequence listing.

[0008] A D-psicose 3-epimerase mutant, the amino acid sequence of which is shown in SEQ ID NO: 3 in the sequence listing.

[0009] A D-psicose 3-epimerase mutant gene, the nucleotide sequence of which is shown in SEQ ID NO: 4 in the sequence listing.

[0010] Primers for amplifying the D-psicose 3-epimerase gene or the D-psicose 3-epimerase mutant gene.

[0011] A vector containing the D-psicose 3-epimerase gene or the D-psicose 3-epimerase mutant gene.

[0012] The engineered bacteria containing the vector is Bacillus subtilis.

[0013] Application of the engineered bacteria in the preparation of D-psicose.

[0014] Beneficial effects of the present invention: The present invention overcomes the host codon preference and expression amount limitations of the existing D-psicose-3-epimerase in Bacillus subtilis during expression and synthesis, and optimizes the overall expression effect by constructing recombinant genetically engineered bacteria. D-psicose-3-epimerase is obtained without using induced expression and secretory expression, and the obtained intracellular enzyme can isomerize the substrate in the cell without extraction and purification, which simplifies the production process and can greatly save production costs. The present invention uses a site-directed mutagenesis method to obtain a D-psicose-3-epimerase mutant, and the enzyme activity is greatly enhanced compared with the unmutated enzyme. DETAILED DESCRIPTION

[0015] In order to facilitate understanding of the present invention, the present invention will be described more fully below. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0016] Example 1

[0017] Degenerate primers were designed based on the conserved region sequence of the Paenibacillus senegalensis gene, and the cDNA obtained by reverse transcription of the extracted Agrobacterium tumefaciens RNA was used as a template by homologous cloning technology. A gene fragment of about 300 bp was obtained by PCR amplification, and then the full-length cDNA sequence of the gene was cloned by 3' and 5' RACE technology. Sequence analysis showed that the full length of the gene cDNA was 1030 bp, the open reading frame was 870 bp, and it encoded a protein of 289 amino acids. The cloning process of the D-psicose-3-epimerase gene is described in detail below:

[0018] 1. Reverse transcription to generate the first strand of cDNA

[0019] (1) Add the following reagents to a 0.2 mL centrifuge tube: 2 μg of total RNA, 151 μL of 500 μg / mL anchor primer oligo d(T), add water to 15 μL, denature at 70°C for 5 min, and quickly cool on ice.

[0020] (2) Add the following components in order:

[0021] AMV 5×Reaction Buffer 5μL; dNTP Mix, 10mM 1.5μL; RNase Inhibitor 0.5μL; RNA 5μL; AMV RT 1μL; oligodT 1μL; MgCl2 4μL, add water to 20μL.

[0022] (3) After mixing, incubate at 42°C for 30 min, then at 99°C for 5 min, and finally place in a 5°C environment.

[0023] 2. PCR reaction to obtain the intermediate fragment

[0024] (1) Prepare PCR reaction solution:

[0025] 10xPCR buffer (containing Mg 2+ )6μL; reverse transcribed cDNA 2μL; Taq enzyme 0.8μL; Fw primer 1.5μL; Rv primer 1.5μL; dNTP Mix 2μL; add water to 50μL.

[0026] (2) PCR reaction:

[0027] Preheat at 94°C for 3 min; repeat 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s; and extend at 72°C for 10 min.

[0028] 3.3'RACE

[0029] The procedure was carried out according to the Invitrogen 3'RACE System for Rapid Amplification of cDNA Ends, Version 2.0 instruction manual.

[0030] (1) The reverse transcription reaction system is as follows:

[0031] RNA 1μg; 3′RACE reverse transcription primer (5μM) 1μL; 5× reverse transcriptase buffer 2μl; dNTP Mixture (10mM) 1μl; RNase inhibitor (40U / μl) 0.25μl; reverse transcriptase (150U / μl) 0.3μl; RNase-free deionized water 5μl; total volume 10μl.

[0032] (2) The reaction conditions are as follows:

[0033] 30℃10min; 42℃60min; 99℃5min; 5℃5min.

[0034] (3) Nested PCR reaction

[0035] Using TaKaRa LA (TaKaRa Code: DRR02AM) The experimental operation for PCR reaction is as follows:

[0036] In the first round of PCR reaction, the reaction system is as follows:

[0037] 10 μL of the above reverse transcription reaction solution; 2 μL of gene-specific primer 1 (10 μM); 2 μL of 3'RACE first round primer (10 μM); 5 μL of 10×LA Taq Buffer II; 5 μL of 10×LA Taq Buffer II; 3 μL of MgCl (25 mM); LA (5U / μL) 0.5μL; deionized water 27.5μL; total volume 50μL;

[0038] The reaction conditions are as follows:

[0039] Preheat at 96°C for 6 min; repeat 20 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and extend at 72°C for 10 min.

[0040] The second round of PCR reaction, the reaction system is as follows:

[0041] 1 μL of the previous round of PCR product; 2 μL of dNTP Mixture (2.5 mM each); 10×LA Taq (Mg-free2+ )5μL; MgCl2 (25mM) 3μL; LA Taq (5U / μL) 0.5μL; gene-specific primer 2 (10μM) 2μL; 3′RACE second-round primer (10μM) 2μL; deionized water 34.5μL; total volume 50μL.

[0042] The reaction conditions are as follows:

[0043] Preheat at 96°C for 6 min; repeat 34 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and extend at 72°C for 10 min.

[0044] 4.5'RACE

[0045] The procedure was carried out according to the Invitrogen 5'RACE System for Rapid Amplification of cDNA Ends, Version 2.0 instruction manual.

[0046] (1) Obtaining the first strand of cDNA

[0047] 1. Prepare the reaction solution: 2.5 pmol of synthetic reverse transcription primer; 4 μg of RNA; DEPC H2O to 16 μL.

[0048] 2. Heat at 70℃ for 10 min to denature the RNA, then place on ice for 1 min, centrifuge, and then add the following components: 2.5μL of 10xPCR buffer; 2.5μL of 25mM MgCl2; 1μL of 10mM dNTP; 2.5μL of 0.1M DTT; 16μL of the reaction solution prepared in step 1.

[0049] 3. Centrifuge to mix the system in step 2 and incubate at 42°C for 1 min.

[0050] 4. Add 1 μL reverse transcriptase SuperscriptTMⅡRT and mix well.

[0051] 5. Incubate at 70℃ for 15 min to terminate the reaction.

[0052] 6. Centrifuge for 10-20 seconds and then place at 37°C.

[0053] 7. Add 1 μl RNase Mix, mix gently, and place at 37°C for 30 minutes to degrade the RNA in the cDNA:RNA chain.

[0054] 8. Collect the sample by centrifugation and place on ice.

[0055] (2) SNAP removes proteins, dNTPs, primers, and DNA contained in cDNA.

[0056] 1. Place the binding solution at room temperature;

[0057] 2. For each purified sample, take about 100 μL of sterile water and preheat it at 65°C for later use;

[0058] 3. Add 120 μL of binding solution to the cDNA solution;

[0059] 4. Add the binding solution / cDNA to the column and centrifuge at 12000 rpm for 20 seconds;

[0060] 5. Remove the adsorption column from the collection tube, transfer the liquid in the tube to another centrifuge tube, save the solution until the cDNA is recovered, and then put the adsorption column back into the collection tube;

[0061] 6. Add 400 μL of ice-cold 1x eluent to the column, centrifuge at 12,000 rpm for 20 seconds, discard the eluent, and repeat this process 4 times;

[0062] 7. Wash the column with 400 μL 70% ethanol and wash twice according to step 6;

[0063] 8. After elution, discard 70% ethanol and spin at 12000 rpm for 1 min;

[0064] 9. Place the column in a new sample collection tube, add about 50 μL of sterile distilled water preheated at 65°C to the column, and then centrifuge at 13,000 rpm for 20 seconds to collect cDNA.

[0065] (3) TdT tail

[0066] 1. Prepare the reaction solution: DEPC H2O 6.5μL; 5x tailing buffer 5.0μL; 2Mm dCTP 2.5μL; column purified cDNA 10.0μL.

[0067] 2. Incubate at 94°C for 2-3 minutes, then immediately place on ice for 1 minute, collect the sample by centrifugation, and then place on ice;

[0068] 3. Add 1 μL of TdT to the centrifuge tube, mix gently, and then incubate at 37°C for 10 min;

[0069] 4. Heat at 65°C for 10 min, then collect the sample by centrifugation.

[0070] (4) PCR reaction

[0071] 1. The reaction system for one round of PCR reaction is as follows:

[0072] 10x PCR buffer 5μL; 25mM MgCl2 3μL; 10mM dNTPs 1μL; outer primer 2μL; AAP 2μL; dC-tailed cDNA 5μL; Taq enzyme 0.5μL; H2O 31.5μL.

[0073] The reaction conditions are as follows:

[0074] Preheat at 94°C for 5 min; repeat 32 cycles of 94°C for 30 s, 55°C for 45 s, and 72°C for 1 min; and extend at 72°C for 10 min.

[0075] 2. The reaction system of the second round of PCR reaction is as follows:

[0076] 10x PCR buffer 5μL; 25mM MgCl2 3μL; 10mM dNTPs 1μL; inner primer 2μL; AUAP 2μL; first round DNA 1μL; Taq enzyme 0.5μL; deionized water 35.5μL.

[0077] The reaction conditions are as follows:

[0078] Preheat at 94°C for 4 min; repeat 32 cycles of 94°C for 30 s, 55°C for 45 s, and 72°C for 1 min; and extend at 72°C for 10 min.

[0079] 5. Obtaining the full length

[0080] (1) Splicing is performed based on the 3' and 5' sequencing sequences, and then primers are designed from both ends of the coding frame. Appropriate restriction sites are added to the 5' ends of the primers to perform PCR from cDNA and genomic DNA.

[0081] (2) The reaction system is as follows:

[0082] 10xEx buffer 5μL; 10xEx buffer 5μL; dNTPs 2μL; upstream primer 1.5μL; downstream primer 1.5μL; Ex Taq 0.5μL; DNA or cDNA 1μL; deionized water 38.5μL

[0083] (3) The reaction conditions are as follows:

[0084] Preheat at 94°C for 5 min; repeat 32 cycles of 94°C for 30 s, 55°C for 45 s, and 72°C for 1 min; total extension at 72°C for 10 min;

[0085] The obtained D-psicose-3-epimerase gene of Agrobacterium tumefaciens was used to construct a prokaryotic expression vector, which was then transferred into an engineered Escherichia coli bacterium.

[0086] Example 2

[0087] Using Bacillus subtilis WB600 as the starting strain, the DP3E sequence derived from Agrobacterium tumefaciens is optimized in the promoter, ribosome binding site and coding sequence on the Bacillus subtilis replicable vector to achieve efficient expression and subsequent efficient catalytic conversion of fructose to D-psicose. The nucleotide sequence is shown in the sequence table SEQ ID NO: 1; the amino acid sequence of the encoded protein is shown in the sequence table SEQ ID NO: 2, and the nucleotide sequence encoding these amino acid sequences. The promoter and ribosome binding site after expression optimization are shown in the sequence table SEQ ID NO: 3.

[0088] Primers were designed to amplify the replication-related functional sequences of the pMA5 vector. The primer sequences used are as follows:

[0089] pMA5F aattacgcgtttcggtgatgacggtgaaa;

[0090] pMA5R taatgctagcgttttgtctagcttaccgaa;

[0091] PCR reaction conditions: using pMA5 empty vector as template, 95℃3min: 95℃30s, 56℃30s, 72℃2min, 30 cycles; 72℃10min, permanent insulation at 4℃.

[0092] Purification and recovery of PCR amplified products: Spot the PCR amplified products for nucleic acid gel agarose gel electrophoresis, observe the band position, cut out the required gel block and strictly follow the steps in the nucleic acid gel recovery kit operation guide to purify the target gene.

[0093] The expression vector pMA5 amplified sequence was double-digested with NhEI and MluI as the restriction sites, and the digested product was verified by nucleic acid gel and recovered and purified. The recovery step was performed according to the instructions of the gel recovery kit. The target gene fragment was connected to the linearized plasmid after digestion using a ligase to obtain the recombinant plasmid PMA-DP3E.

[0094] Construction and expression of recombinant bacteria:

[0095] (1) Construction of amplification strain: The recombinant plasmid PMA-DP3E was transformed into Escherichia coli DH5α by chemical transformation for plasmid amplification. After successful colony PCR, it was inoculated into 10 mL LB solid culture medium and cultured at 37°C, 180 rpm for 10 h. The plasmids were extracted using a bacterial plasmid extraction kit.

[0096] (2) Construction of recombinant strains: The amplified plasmid was introduced into Bacillus subtilis WB600 by chemical transformation. After colony PCR verification, the obtained recombinant strains were inoculated into 10 mL of LB solid culture medium and cultured at 37°C and 180 rpm for 10 h to obtain the recombinant strains B. subtilis WB600 / pMA-DP3E. The strains were stored at -80°C.

[0097] Example 3

[0098] In order to improve the activity of D-psicose 3-epimerase, the inventors used bioinformatics to predict potential active amino acid sites, and predicted amino acid sites that may play a key role, including the 16th position; the 34th position, the 35th position; the 112th position, and the 113th position.

[0099] Using pMA-DP3E vector as a template, mutants were obtained by site-directed mutagenesis, with the mutation sites being amino acid residue A at position 16 mutated to E; amino acid residues EV at positions 34 and 35 mutated to DA; and amino acid residues WP at positions 112 and 113 mutated to AA.

[0100] The designed mutation primers are as follows:

[0101] FR1: 5′-GAACATGAATGGTCGGAGAAATTTG-3′ (mutation at position 16);

[0102] PR1: 5′-ACGGGCCAAATTTCTCCGACCATTCAT-3′ (mutation at position 16);

[0103] FR2: 5′-GGGCTTTGATATTATTGACGCCGCGGC-3′ (mutations at positions 34 and 35);

[0104] PR2: 5′-TGGGCCGCGGCGTCAATAATATCAAAG-3′ (mutations at positions 34 and 35);

[0105] FR3: 5′-TGCATAGCTATGCGGCGATTGATTA-3′ (mutations at positions 112 and 113);

[0106] PR3: 5′-ATCAATCGCCGCATAGCTATGCAGCGCGC-3′ (mutations at positions 112 and 113);

[0107] The obtained pMA-DP3E vector was used as a template for whole plasmid PCR; PCR reaction system: 10×Pyrobest buffer, 5μl; dNTP (2.5mM), 5μl; mutation primer FP (20μM), 1μl; mutation primer RP (20μM), 1μl; Pyrobest, 0.3μl; template, 1μl; add ddH2O to 50μl.

[0108] The mutant expression vectors pMA-DP3E'1 (mutation at position 16), pMA-DP3E'2 (mutation at positions 34 and 35), and pMA-DP3E'3 (mutation at positions 112 and 113) were obtained respectively. The recombinant bacteria were constructed and expressed by the method of Example 1 to obtain the recombinant strains B. subtilisWB600 / pMA-DP3E'1, B. subtilisWB600 / pMA-DP3E'2, and B. subtilisWB600 / pMA-DP3E'1, and the strains were stored at -80°C.

[0109] Example 4

[0110] Expression of recombinant bacteria and determination of enzyme activity: The obtained Bacillus subtilis recombinant strain was transferred to 10 mL LB liquid medium and cultured at 37°C and 180 rpm for 10 h to obtain seed solutions containing the recombinant strain. The above-obtained seed solutions were transferred to 100 mL SOC medium at an inoculum amount of 1% (v / v) and cultured at 37°C and 180 rpm for 4 h to express D-psicose 3-epimerase and obtain crude enzyme solutions containing D-psicose 3-epimerase.

[0111] D-psicose-3-epimerase-catalyzed fructose conversion method:

[0112] 1) Plate colony culture: Streak the preserved production strain on a plate solid culture medium and culture it at 37°C for 12 hours to obtain a single colony.

[0113] 2) Seed culture: Pick a single colony and inoculate it into liquid culture medium, and culture it in a shaking incubator at 150 rpm for 12 h to obtain seeds.

[0114] 3) Expression of psicose-3-epimerase in bacterial strains The seeds were inoculated into a 2 L fermenter at an inoculation rate of 15% by volume of the liquid culture medium. The total volume of the culture medium in the fermenter was 1 L, and high-density culture was performed to obtain a large number of bacterial cells containing psicose-3-epimerase.

[0115] 4) Obtaining Cultured Bacteria The cultured bacteria were obtained by centrifugation at 5000 rpm for 10 minutes and resuspended in 1 / 10 volume of 50 mM Tris-HCl (pH 7.5) buffer solution.

[0116] 5) Production of D-psicose Fructose was added to the resuspended cells at an amount of 30 g / L, and the reaction was carried out at 45° C. and 150 rpm for 3 h. The D-psicose yield in the system was detected.

[0117] The detection method of D-psicose is HPLC detection conditions: RID detector, mobile phase ultrapure water, chromatographic column Hi-Plex-Ca30×7.7mm, column temperature 80℃, detection temperature 55℃, flow rate 0.4mL / min, and the specific value is determined by comparison with the standard. D-psicose 3-epimerase activity unit: The amount of enzyme required to catalyze the formation of 1 mol of D-psicose within 1 minute is defined as one enzyme activity unit. D-psicose 3-epimerase specific enzyme activity: One unit of enzyme activity is defined as the amount of enzyme required to catalyze the formation of 1 μmol of D-psicose per minute under the assay conditions (U / mg).

[0118] The results showed that the specific enzyme activity of D-psicose 3-epimerase in the bacterial culture broth obtained with the recombinant strain B. subtilisWB600 / pMA-DP3E as the fermentation bacterium was 175 U / mg; the specific enzyme activity of D-psicose 3-epimerase in the bacterial culture broth obtained with the recombinant strain B. subtilisWB600 / pMA-DP3E'1 as the fermentation bacterium was 176 U / mg; the specific enzyme activity of D-psicose 3-epimerase in the bacterial culture broth obtained with the recombinant strain B. subtilisWB600 / pMA-DP3E'2 as the fermentation bacterium was 278 U / mg; and the specific enzyme activity of D-psicose 3-epimerase in the bacterial culture broth obtained with the recombinant strain B. subtilisWB600 / pMA-DP3E'3 as the fermentation bacterium was 123 U / mg.

[0119] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A D-psicose 3-epimerase mutant, characterized in that: Its amino acid sequence is shown in SEQ ID NO: 4 in the sequence listing.

2. A D-psicose 3-epimerase mutant gene, characterized in that: The nucleotide sequence is shown in SEQ ID NO: 5 in the sequence listing.

Citation Information

Patent Citations

  • Hyaluronan synthase mutant and application thereof

    CN105838688A

  • Mutant of D-allulose-3-epimerase and application thereof

    CN106148311A

  • DPEase (D-psicose-3-epimerase) mutant, and coding gene, recombinant vector, recombinant strain and application thereof

    CN110684762A

  • Psicose 3-epimerase mutant, engineering bacterium for expressing mutant and application thereof

    CN112852795A

  • New-source D-psicose-3-epimerase gene and application method thereof

    CN113005132A